Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Asia 2022 | Identifying patients with HCC who will respond best to IO

Stephen L. Chan, MBBS (HK), MRCP (UK), FHKCP, FHKAM (Medicine), FRCP (Edin), FRCP (Lond), Chinese University of Hong Kong, Hong Kong, discusses the main unmet needs for the use of immunotherapy (IO) for patients with hepatocellular carcinoma (HCC), including the need to identify patients who are ‘super-responsive’ to IO. This interview took place at the European Society for Medical Oncology (ESMO) Asia congress 2022 in Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.